June 4, 2011 (Chicago, Illinois) — The aromatase inhibitor exemestane offers a new option for breast cancer prevention in postmenopausal women at high risk for the disease. Data from the Mammary ...
January 18, 2011 — Exemestane used alone for 5 years is similar to exemestane used after 2 to 3 years of tamoxifen in the prevention of relapse in postmenopausal women with hormone-responsive early ...
Selective estrogen-receptor modulators (tamoxifen [Nolvadex, Soltamox], raloxifene [Evista]) have been shown to reduce the risk of breast cancer in postmenopausal women, but also have been associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results